Dr Emma Svennberg, cardiologist in Stockholm and first author of the consensus paper, noted that modern AF care requires a more streamlined and holistic approach. She highlighted the need to address ...

The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Svennberg E et al. Transforming Atrial Fibrillation Management by Targeting Comorbidities and Reducing Atrial Fibrillation Burden: the 10th AFNET/EHRA Consensus Conference. Europace, 15 Dec 2025. DOI: ...

Key takeawaysAn international panel of more than 80 experts has issued updated guidance to improve care for atrial fibrillation (AF) patients ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

Objective Patients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the ...

Medications for arrhythmia include antiarrhythmic drugs that restore the heart’s normal rhythm by affecting the heart’s electrical current. Calcium channel blockers can help manage arrhythmia, angina, ...

Demonstrating that the best solution is not always a multistage approach, a new trial showed catheter ablation is superior to a combination of antiarrhythmic drugs and lifestyle changes — weight loss, ...